<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        25-100-98
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VAGIFEM 25MICROGRAM- VAGINAL TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESTRADIOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Vaginal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Applicator
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        32.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03CA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vagifem<sup>&reg;</sup> contains estradiol</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Estradiol is a female sex hormone.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It belongs to a group of hormones called oestrogens.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is exactly the same as the estradiol produced by the ovaries of women.</p><p>Vagifem<sup>&reg;</sup> belongs to a group of medicines called local Hormone Replacement Therapy (HRT).</p><p><strong>It is used to</strong> relieve menopausal symptoms in the vagina such as dryness or irritation. In medical terms, this is known as &lsquo;vaginal atrophy&rsquo;. It is caused by a drop in the levels of oestrogen in your body. This happens naturally after the menopause.</p><p>&nbsp;</p><p><strong>Vagifem<sup>&reg;</sup> works by</strong> replacing the oestrogen which is normally produced in the ovaries of women. It is inserted into your vagina, so the hormone is released where it is needed. This may relieve discomfort in the vagina.</p><p>&nbsp;</p><p>The experience of treating women older than 65<strong> </strong>years is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Medical history and regular check-ups</strong></p><p>The use of HRT carries risks which need to be considered when deciding whether to start taking it, or whether to carry on taking it.</p><p>&nbsp;</p><p>Before you start (or restart) HRT, your doctor will ask about your own and your family&rsquo;s medical history. Your doctor may decide to perform a physical examination. This may include an examination of your breasts and/or internal examination, if necessary.</p><p>&nbsp;</p><p>Go for regular<strong> </strong>breast screening as recommended by your doctor.</p><p>&nbsp;</p><p><strong>Do not use Vagifem<sup>&reg;</sup>:</strong></p><p>If any of the following applies to you.</p><p>Do not use Vagifem<sup>&reg;</sup> if</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are <strong>allergic</strong> (hypersensitive) to <strong>estradiol</strong> or any of the other ingredients of Vagifem<sup>&reg;</sup> (listed in section 6 <em>Further information</em>).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have or have ever had <strong>breast cancer,</strong> or you are suspected of having it.</p><p>You have or have ever had <strong>cancer which is sensitive to oestrogens,</strong> such as cancer of the womb lining (endometrium), or you are suspected of having it.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have <strong>any unexplained vaginal bleeding.</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have <strong>excessive thickening of the womb lining</strong> (endometrial hyperplasia) that is not being treated.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have or have ever had a <strong>blood clot</strong> <strong>in a vein</strong> (thrombosis) such as in the legs (deep venous thrombosis) or the lungs (pulmonary embolism).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a <strong>blood clotting disorder</strong> (such as protein C, protein S or antithrombin deficiency).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have or have previously had a disease caused by blood clots in the arteries, such as a <strong>heart attack, stroke or angina.</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have or have ever had a <strong>liver disease</strong> and your liver function tests have not returned to normal.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a rare blood problem called <strong>&lsquo;porphyria&rsquo;,</strong> which is passed down in families (inherited).</p><p>If you are not sure about any of the points above, <strong>talk to your doctor</strong> before using Vagifem<sup>&reg;</sup>.</p><p>&nbsp;</p><p>If any of the above conditions appear for the first time while using Vagifem<sup>&reg;</sup>, stop using it at once and consult your doctor immediately.</p><p>&nbsp;</p><p><strong>When to take special care with Vagifem<sup>&reg;</sup></strong></p><p>Tell your doctor if you have or have ever had any of the following problems before you start the treatment. If so, you should see your doctor more often for check-ups. Vagifem<sup>&reg;</sup>, as opposed to systemic oestrogen, is for local treatment in the vagina, and the absorption into the blood is very low. It is therefore less likely that the conditions mentioned below will get worse or come back during treatment with Vagifem<sup>&reg;</sup>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epilepsy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gallstones</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraines or severe headaches</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A liver disorder, such as a benign liver tumour</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth of womb lining outside your womb (endometriosis) or a history of excessive growth of the womb lining (endometrial hyperplasia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A disease affecting the eardrum and hearing (otosclerosis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A disease of the immune system that affects many organs of the body (systemic lupus erythematosus, SLE)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased risk of getting an oestrogen-sensitive cancer (such as having a mother, sister or grandmother who has had breast cancer)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased risk of developing blood clots (see <em>Blood clots in a vein (thrombosis)</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fibroids inside your womb</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A very high level of fat in your blood (triglycerides)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid retention due to cardiac or kidney problems.</p><p>&nbsp;</p><p><strong>Stop using Vagifem<sup>&reg;</sup> and see a doctor immediately</strong></p><p>If you notice any of the following when using HRT:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine-like headaches which happen for the first time</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of your skin or the whites of your eyes (jaundice). These may be signs of a liver disease</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A large rise in your blood pressure (symptoms may be headache, tiredness, dizziness)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any of the conditions mentioned in the <em>Do not use Vagifem<sup>&reg;</sup> </em>section</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you become pregnant</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you notice signs of a blood clot, such as:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful swelling and redness of the legs</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden chest pain</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing.</p><p>For more information, see <em>Blood clots in a vein (thrombosis).</em></p><p>&nbsp;</p><p>The following risks apply to HRT medicines which circulate in the blood. It is not known how these risks apply to locally administered treatments such as Vagifem<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>HRT and cancer </strong></p><p>&nbsp;</p><p><strong>Excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer)</strong></p><p>Taking oestrogen-only HRT tablets for a long time can increase the risk of developing cancer of the womb lining<strong> </strong>(the endometrium). It is uncertain whether long term (more than one year) or repeated use of local vaginally administered oestrogen products possess a similar risk.</p><p>&nbsp;</p><p>Vagifem<sup>&reg;</sup> has been shown to have very low systemic absorption initially during treatment, and the addition of a progestagen is therefore not necessary.</p><p>&nbsp;</p><p>If you get<strong> breakthrough bleeding </strong>or<strong> spotting,</strong> it is usually nothing to worry about, but you should make an appointment to see your doctor. It could be a sign that your endometrium has become thicker.</p><p>&nbsp;</p><p><em>Compare</em></p><p>In women who still have a womb and who are not taking HRT, on average, 5 in 1,000 will be diagnosed with endometrial cancer between the ages of 50 and 65.</p><p>For women aged 50 to 65 who still have a womb and who take oestrogen-only HRT, between 10 and 60 women in 1,000 will be diagnosed with endometrial cancer (i.e. between 5 and 55 extra cases), depending on the dose and for how long it is taken.</p><p>&nbsp;</p><p><strong>Breast cancer </strong></p><p>Evidence suggests that taking combined oestrogen-progestagen and possibly also oestrogen-only HRT increases the risk of breast cancer. The extra risk depends on how long you take HRT. The additional risk becomes clear within a few years. However, it returns to normal within a few years (at most 5) after stopping treatment.</p><p>For women who have had their womb removed and who are using oestrogen-only HRT for 5 years, little or no increase in breast cancer risk is shown.</p><p><em>&nbsp;</em></p><p><em>Compare</em></p><p>Women aged 50 to 79 who are not taking HRT, on average, 9 to 17 in 1,000 will be diagnosed with breast cancer over a 5-year period. For women aged 50 to 79 who are taking oestrogen-progestagen HRT over 5 years, there will be 13 to 23 cases in 1,000 users (i.e. an extra 4 to 6 cases).</p><p>&nbsp;</p><p><strong>Regularly check your breasts. See your doctor if you notice any changes such as: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dimpling of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in the nipple</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any lumps you can see or feel.</p><p>&nbsp;</p><p><strong>Ovarian cancer </strong></p><p>Ovarian cancer is rare &ndash; much rarer than breast cancer. The use of oestrogen-only HRT has been associated with a slightly increased risk of ovarian cancer.</p><p>&nbsp;</p><p><em>Compare</em></p><p>The risk of ovarian cancer varies with age. For example, in women aged 50 to 54 who are not taking HRT, about 2 women in 2,000 will be diagnosed with ovarian cancer over a 5-year period. For women who have been taking HRT for 5 years, there will be about 3 cases per 2,000 users (i.e. about 1 extra case).</p><p>&nbsp;</p><p><strong>Effect of HRT on heart and circulation </strong></p><p>&nbsp;</p><p><strong>Blood clots in a vein (thrombosis) </strong></p><p>The risk of <strong>blood clots in the veins </strong>is about 1.3- to 3-times higher in HRT users than in non-users, especially during the first year of taking it.</p><p>Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, fainting or even death.</p><p>&nbsp;</p><p>You are more likely to get a blood clot in your veins as you get older and if any of the following applies to you. Inform your doctor if any of these situations applies to you:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are unable to walk for a long time because of major surgery, injury or illness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are seriously overweight (BMI &gt;30 kg/m&sup2;)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any blood clotting problem that needs long-term treatment with a medicine used to prevent blood clots</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if any of your close relatives has ever had a blood clot in the leg, lung or another organ</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have systemic lupus erythematosus (SLE)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have cancer.</p><p>&nbsp;</p><p>For signs of a blood clot, see <em>Stop using Vagifem<sup>&reg;</sup> and see a doctor immediately.</em></p><p>&nbsp;</p><p><em>Compare</em></p><p>Looking at women in their 50s who are not taking HRT, on average, over a 5-year period, 4 to 7 in 1,000 would be expected to get a blood clot in a vein.</p><p>For women in their 50s who have been taking oestrogen-progestagen HRT for over 5 years, there will be 9 to 12 cases in 1,000 users (i.e. 5 extra cases).</p><p>For women in their 50s who have had their womb removed and have been taking oestrogen-only HRT for over 5 years, there will be 5 to 8 cases in 1,000 users (i.e. 1 extra case).</p><p>&nbsp;</p><p><strong>Heart disease (heart attack) </strong></p><p>There is no evidence that HRT will prevent a heart attack.</p><p>Women over the age of 60 years who use oestrogen-progestagen HRT are slightly more likely to develop heart disease than those not taking any HRT.</p><p>For women who have had their womb removed and are taking oestrogen-only therapy there is no increased risk of developing a heart disease.</p><p>&nbsp;</p><p><strong>Stroke </strong></p><p>The risk of getting stroke is about 1.5 times higher in HRT users than in non-users. The number of extra cases of stroke due to use of HRT will increase with age.</p><p>&nbsp;</p><p><em>Compare </em></p><p>Looking at women in their 50s who are not taking HRT, on average, 8 in 1,000 would be expected to have a stroke over a 5-year period. For women in their 50s who are taking HRT, there will be 11 cases in 1,000 users, over 5 years (i.e. 3 extra cases).</p><p>&nbsp;</p><p><strong>Other conditions</strong></p><p>HRT will not prevent memory loss. There is some evidence of a higher risk of memory loss in women who start using HRT after the age of 65. Speak to your doctor for advice.</p><p>&nbsp;</p><p><strong>Using other medicines</strong></p><p>Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription. However, Vagifem<sup>&reg;</sup> is not likely to affect other medicines. This is because Vagifem<sup>&reg;</sup> is used for a local treatment in the vagina and contains a very low dose of estradiol.</p><p><em>&nbsp;</em></p><p><strong>Pregnancy and breast-feeding</strong></p><p>Vagifem<sup>&reg;</sup> is for use in post-menopausal women only. If you become pregnant, stop using Vagifem<sup>&reg;</sup> and contact your doctor.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>No known effect.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Vagifem<sup>&reg;</sup> exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Using this medicine</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can start using Vagifem<sup>&reg;</sup> on any day which is best for you.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the vaginal tablet into your vagina with the applicator.</p><p>&nbsp;</p><p>The &lsquo;USER INSTRUCTIONS&rsquo; at the end of the leaflet tell you how to do this. Read the instructions carefully before using Vagifem<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use one vaginal tablet each day for the first 2 weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then use one vaginal tablet twice a week. Leave 3 or 4 days between each dose.</p><p>&nbsp;</p><p><strong>General information about treating symptoms of the menopause</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When using medicines for any menopausal symptoms, it is recommended to use the lowest dose that works, and to use the medicine for as short a time as it is needed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment should only be continued if the benefit is greater than the risk. Talk to your doctor about this.</p><p>&nbsp;</p><p><strong>If you use more Vagifem<sup>&reg;</sup> than you should</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have used more Vagifem<sup>&reg;</sup> than you should, talk to a doctor or pharmacist.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vagifem<sup>&reg;</sup> is for local treatment inside the vagina. The dose of estradiol is so low that a considerable number of tablets would have to be taken to approach the dose normally used for treatment taken by mouth.</p><p>&nbsp;</p><p><strong>If you forget to use Vagifem<sup>&reg;</sup> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget a dose, use the medicine as soon as you remember.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Vagifem<sup>&reg;</sup> </strong></p><p>Do not stop using Vagifem<sup>&reg;</sup> without talking to your doctor. Your doctor will explain the effects of stopping treatment. He or she will also discuss other possibilities for treatment with you.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Vagifem<sup>&reg;</sup> can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain, discomfort or distension</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal bleeding, discharge or discomfort.</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An infection of the genitals caused by a fungus</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increase</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flush</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension.</p><p>&nbsp;</p><p><strong>Very rare side effects </strong>(may affect up to 1 in 10,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine aggravated</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generalised hypersensitivity (e.g. anaphylactic reaction/shock).</p><p>&nbsp;</p><p><strong>The following side effects can occur with systemic oestrogen treatment:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gall bladder disease</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Various skin disorders:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discoloration of the skin especially of the face or neck known as &lsquo;pregnancy patches&rsquo; (chloasma)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful reddish skin nodules (erythema nodosum)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash with target-shaped reddening or sores (erythema multiforme).</p><p>&nbsp;</p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Store below 25&deg;C. Do not refrigerate.</p><p>Do not use Vagifem<sup>&reg;</sup> after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Vagifem<sup>&reg;</sup> contains</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is estradiol 25&nbsp;micrograms (as estradiol hemihydrate). Each vaginal tablet contains 25&nbsp;micrograms estradiol (as estradiol hemihydrate).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other ingredients are: hypromellose, lactose monohydrate, maize starch and magnesium stearate.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The film-coating contains: hypromellose and macrogol 6000.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Each white vaginal tablet comes in an applicator which is used once only. 
Vagifem® is engraved with NOVO 278 on one side.

Pack sizes:
15 vaginal tablets with applicators
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd</p><p>Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong> على الإيستراديول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإيستراديول هو هرمون جنسي أنثوي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي الإيستراديول إلى مجموعة هرمونات تُسمى الإستروجين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مماثل تماماً للإيستراديول الذي يتم إنتاجه في مبايض المرأة.</p><p dir="RTL">ينتمي دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong> إلى مجموعة أدوية تُسمى العلاج الموضعي بالهرمونات البديلة (HRT).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ويتم استعماله</strong> للتخفيف من الأعراض التي تصيب المهبل بعد سن اليأس، مثل الجفاف أو التهيج. وفي المصطلحات الطبية، يُعرف ذلك باسم &quot;الضمور المهبلي&quot;. ويرجع حدوثه إلى الانخفاض العالي في مستويات الإستروجين في الجسم. ويعد هذا أمراً طبيعياً بعد سن انقطاع الطمث.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يعمل دواء فاجيفم</strong>TM عن طريق تعويض الإستروجين الذي يتم إنتاجه طبيعياً في مبايض المرأة. يتم إدخال القرص في المهبل، فيتم تحرير الهرمون في المكان المطلوب به. وقد يعمل ذلك على تخفيف الاضطرابات المهبلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعد تجربة علاج السيدات الأكبر من 65 عاماً محدودة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>التاريخ الطبي للمريض والفحوصات الطبية الدورية</strong></p><p dir="RTL">توجد بعض المخاطر المحتملة لاستخدام العلاج بالهرمونات البديلة (HRT) والتي يجب وضعها في الاعتبار قبل اتخاذ القرار ببدء تناول هذا العقار أو الاستمرار في تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل البدء (أو إعادة البدء) في استخدام العلاج بالهرمونات البديلة، سوف يسألكِ الطبيب عن تاريخِك الطبي وعن التاريخ الطبي لعائلتك أيضاً. وقد يطلب الطبيب إجراء فحص طبي. ويشمل ذلك فحص الثديين و/أو إجراء فحص داخلي، إذ لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عمل فحص دوري للثدي للكشف المبكر عن أورام الثدي، وفقاً لما يوصي به طبيبِك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحظر استعمال دواء فاجيفم</strong><strong><sup>TM</sup></strong><strong>:</strong></p><p dir="RTL">إذا كانت أيٌ من الحالات التالية تنطبق عليكِ.</p><p dir="RTL">يحظر استعمال <strong>فاجيفم</strong><strong><sup>TM</sup></strong> في الحالات التالية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من <strong>حساسية</strong> (فرط الحساسية) تجاه <strong>الإيستراديول</strong> أو أيٍ من مكونات <strong>فاجيفم</strong><strong><sup>TM</sup></strong> (المدرجة في القسم 6، <em>معلومات أخرى</em>).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة بمرض <strong>سرطان الثدي</strong> أو كان قد حدث لكِ من قبل، أو إذا كان مشكوكاً في وجوده.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة، أو أصبتِ، بأي نوع من <strong>السرطان الحساس لهرمون الإستروجين،</strong> مثل سرطان بطانة الرحم (الغشاء المبطن للرحم)، أو إذا كان مشكوًكاً في وجوده.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود <strong>أي نزيف مهبلي غير معروف سببه.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود <strong>سماكة مفرطة في بطانة الرحم</strong> (فرط تنسج بطانة الرحم) لم تتم معالجتها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود <strong>جلطة دموية</strong> <strong>في أحد الأوردة</strong> (تخثر) أو حدوثها من قبل، في أماكن مثل الأرجل (خثار وريدي عميق) أو الرئتين (انصمام رئوي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من <strong>اضطرابات تتسبب في تجلط الدم</strong> (مثل نقص بروتين C أو بروتين S أو مضاد الثرومبين).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين أو أصبتِ من قبل بمرض بسبب حدوث جلطات دموية في الشرايين، مثل <strong>النوبة القلبية أو السكتة الدماغية أو الذبحة الصدرية.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة <strong>بمرض في الكبد</strong> أو سبق حدوثه لكِ ولم تعد نتائج اختبارات وظائف الكبد إلى معدلاتها الطبيعية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديكِ مشكلة نادرة في الدم تُسمى <strong>&quot;داء البرفيرية&quot;</strong> وهو مرض وراثي في العائلات (متوارث).</p><p dir="RTL">إذا كنتِ غير متأكدة من النقاط المذكورة أدناه، <strong>فيجب التحدث مع طبيبِك</strong> قبل أخذ دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة ظهور أي من الحالات المذكورة أعلاه لديكِ لأول مرة أثناء استخدام دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong>، فيجب التوقف عن تناوله فوراً واستشارة الطبيب في الحال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى يجب توخي الحذر عند استخدام دواء فاجيفم</strong><strong><sup>TM</sup></strong></p><p dir="RTL">أخبري طبيبك إذا كنتِ تعانين من أيٍ من المشكلات التالية أو إذا كانت قد حدثت لكِ سابقاً، قبل بدء العلاج. وفي هذه الحالة، يجب زيارة طبيبِك بمعدل أكثر تكراراً لإجراء الفحوصات الطبية. على عكس الإستروجين الجهازي، يعمل دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong> كعلاج موضعي في المهبل، ويكون امتصاصه في الدم بطيئاً جداً. لذا، فإنه يوجد احتمال ضعيف بأن تسوء الحالات المذكورة أدناه أو تعود مرة أخرى أثناء العلاج بدواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصرع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحصوات الصفراوية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي أو الصداع الحاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الكبد، مثل ورم حميد في الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمو بطانة الرحم خارج الرحم (الانتباذ البطاني الرحمي) أو وجود تاريخ للنمو المفرط لبطانة الرحم (فرط تنسج بطانة الرحم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يؤثر على طبلة الأذن والسمع (تصلب الأذن)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض في الجهاز المناعي يؤثر على عدة أعضاء في الجسم (الذئبة الحمامية المجموعية، SLE)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مخاطر الإصابة بسرطان حساس للإستروجين (مثل إصابة الأم أو الأخت أو الجدة بمرض سرطان الثدي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مخاطر تطور جلطات دموية (راجعي <em>الجلطات الدموية في الوريد (التخثر)</em>)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود أورام ليفية في الرحم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع حاد في مستوى الدهون في الدم (الدهون الثلاثية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل بسبب مشكلات في الكلى أو القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقفي عن استخدام دواء فاجيفم</strong><strong><sup>TM</sup></strong><strong> وقومي بزيارة طبيبك على الفور</strong></p><p dir="RTL">في حال ملاحظة أي من التالي عند استخدام العلاج بالهرمونات البديلة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع شبيه بالصداع النصفي يحدث لأول مرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو بياض العينين (اليرقان) فقد تكون هذه الأعراض علامات لوجود مرض في الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع كبير في ضغط الدم (قد تكون الأعراض عبارة عن صداع وشعور بالإجهاد ودوار)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيٌ من الحالات المذكورة في قسم <em>يحظر استعمال دواء </em><strong>فاجيفم</strong><strong><sup>TM</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال حدوث حمل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظتِ علامات لجلطة دموية، مثل:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تورم مؤلم واحمرار في الساقين</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم مفاجئ في الصدر</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">لمزيد من المعلومات، يرجي مراجعة قسم <em>الجلطات الدموية في الوريد (التخثر).</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">تنطبق المخاطر التالية على أدوية العلاج بالهرمونات البديلة التي تسري في الدم. وليس معلوماً مدى ارتباط هذه المخاطر بالعلاجات الموضعية مثل دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>العلاج بالهرمونات البديلة </strong><strong>(HRT)</strong><strong> والسرطان </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>السماكة المفرطة لبطانة الرحم (فرط تنسج بطانة الرحم) وسرطان بطانة الرحم</strong></p><p dir="RTL">قد يؤدي أخذ أقراص العلاج بالهرمونات البديلة، التي تحتوي على الإستروجين فقط، لمدة طويلة، إلى زيادة مخاطرة حدوث سرطان بطانة الرحم (الغشاء المبطن للرحم). ولم يتم التأكد مما إذا كان الاستخدام المتكرر أو طويل المدى (لأكثر من سنة) لمنتجات الإستروجين التي يتم أخذها موضعياً في المهبل، له نفس المخاطرة أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد أظهر دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong> أن امتصاصه الجهازي يكون بطئ جداً أولياً أثناء العلاج، وبالتالي لا توجد ضرورة لإضافة بروجستوجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث لكِ <strong>نزيف في منتصف الدورة الطمثية</strong> أو <strong>تبقيع</strong>، فلا توجد عادةً حاجة للقلق، ولكن يجب استشارة طبيبك في ذلك. فقد يكون ذلك مؤشراً على أن الغشاء المبطن للرحم قد أصبح أكثر سماكة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><em>مقارنة</em></p><p dir="RTL">بالنسبة للسيدات اللاتي لم يزلن الرحم ولا يستخدمن العلاج بالهرمونات البديلة، فقد تم تشخيص حوالي 5 حالات من بين 1000 حالة بسرطان بطانة الرحم في المرحلة العمرية ما بين 50 و65 عاماً.</p><p dir="RTL">أما بالنسبة للسيدات ما بين 50 و65 عاماً اللاتي لم يزلن الرحم ويستخدمن هرمون الإستروجين فقط في العلاج بالهرمونات البديلة، فقد تم تشخيص ما بين 10 و60 حالة من بين 1000 حالة بسرطان بطانة الرحم (أي ما بين 5<strong> </strong>و55 حالة إضافية)، وذلك وفقاً للجرعة ومدة تناول الهرمون.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>سرطان الثدي </strong></p><p dir="RTL">تشير الدلائل إلى أن استخدام العلاج بالهرمونات البديلة سواءً باستخدام العلاج المركب من هرموني الإستروجين والبروجستوجين أو ربما باستخدام الإستروجين فقط، يزيد من مخاطر الإصابة بسرطان الثدي. وتعتمد هذه المخاطرة الإضافية على مدة استخدام العلاج بالهرمونات البديلة. تظهر هذه المخاطرة الإضافية خلال بضع سنوات من بدء استخدام العلاج. ورغم ذلك، يعود الأمر إلى معدله الطبيعي خلال سنوات قليلة (5 سنوات على الأكثر) من التوقف عن تناول العلاج.</p><p dir="RTL">بالنسبة للسيدات اللاتي تم استئصال الرحم لديهن واللاتي تستخدمن هرمون الإستروجين فقط في العلاج بالهرمونات البديلة لمدة 5 سنوات، تظهر مخاطر الإصابة بسرطان الثدي منخفضة جداً أو بدون زيادة عن معدلها الطبيعي.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>مقارنة</em></p><p dir="RTL">بالنسبة للسيدات في المرحلة العمرية ما بين 50 و79 عاماً واللاتي لا تستخدمن العلاج بالهرمونات البديلة، فقد تم تشخيص حوالي من 9 إلى 17 حالة من بين 1000 حالة بسرطان الثدي خلال فترة من 5 سنوات. وبالنسبة للسيدات في المرحلة العمرية ما بين 50 و79 عاماً واللاتي تستخدمن العلاج بالهرمونات البديلة باستخدام هرموني الإستروجين والبروجستوجين خلال 5 سنوات، فقد تم تشخيص من 13 إلى 23 حالة من بين 1000 مستخدم بسرطان الثدي (أي من 4 إلى 6 حالات زائدة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عمل فحص دوري للثديين. وقومي بزيارة طبيبك إذا لاحظتِ وجود أية تغيرات، مثل: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود نقرات خفيفة على البشرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغيرات في الحلمة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بأية تكتلات في الثدي أو رؤيتها</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سرطان المبيض </strong></p><p dir="RTL">يعد سرطان المبيض نادراً &ndash; أكثر ندرة بكثير من سرطان الثدي. &rlm;وقد لوحِظ وجود ارتباط بين استخدام العلاج بالهرمونات البديلة باستخدام هرمون الإستروجين فقط ووجود زيادة ضئيلة في نسبة مخاطرة الإصابة بسرطان المبيض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>مقارنة</em></p><p dir="RTL">&rlm;تختلف مخاطرة الإصابة بسرطان المبيض وفقاً لعمر السيدة. فعلى سبيل المثال، بالنسبة للسيدات في المرحلة العمرية ما بين 50 و54 عاماً واللاتي لا تستخدمن العلاج بالهرمونات البديلة، فقد تم تشخيص حوالي حالتين من بين 2000 حالة بسرطان المبيض خلال فترة من 5 سنوات. أما بالنسبة للسيدات اللاتي تستخدمن العلاج بالهرمونات البديلة لمدة 5 سنوات، يتم تشخيص حوالي 3 حالات بسرطان المبيض من بين 2000 سيدة (أي زيادة حوالي حالة واحدة).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير العلاج بالهرمونات البديلة على القلب والدورة الدموية </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجلطات الدموية في الوريد (التخثر) </strong></p><p dir="RTL">تعد مخاطر الإصابة <strong>بالجلطات الدموية في الوريد</strong> أعلى بمقدار من 1.3 حتى 3 مرات لدى السيدات اللاتي تستخدمن العلاج بالهرمونات البديلة مقارنةً باللاتي لا تستخدمن هذا العلاج، وخاصةً أثناء أول سنة من تناول العلاج.</p><p dir="RTL">من الممكن أن تؤدي الجلطات الدموية إلى نتائج خطيرة، وإذا انتقلت إحدى الجلطات إلى الرئتين، فقد تتسبب في وجود آلام بالصدر أو عسر تنفس أو إغماء أو ربما الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكوني عرضة بنسبة كبيرة لحدوث جلطة دموية في الأوردة كلما كبر سنِك وإذا كان أيٌ مما يلي ينطبق عليكِ. يجب إخبار طبيبِك إذا كنتِ تعانين من أيٍ من الحالات التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستطيعين المشي منذ فترة طويلة بسبب جراحة كبرى أو إصابة أو مرض</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توجد زيادة كبيرة في الوزن (مؤشر كتلة الجسم (BMI) &lt; 30 كغ/م&sup2;)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توجد لديكِ أية مشكلة مزمنة في تجلط الدم تحتاج إلى علاج طويل الأجل وتستخدمين دواءً لمنع الجلطات الدموية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدث لأحد أفراد عائلتك أية جلطة دموية في الساق أو الرئة أو أي عضو آخر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانين من مرض الذئبة الحمامية المجموعية (SLE)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة بالسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للتعرف على علامات الجلطة الدموية، راجعي قسم، <em>توقفي عن استخدام دواء </em><strong>فاجيفم</strong><strong><sup>TM</sup></strong><em> وقومي بزيارة طبيبك على الفور.</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>مقارنة</em></p><p dir="RTL">بالنسبة للسيدات في الخمسينات من العمر واللاتي لا تستخدمن العلاج بالهرمونات البديلة على مدى 5 سنوات، فمن المتوقع، في المتوسط، حدوث جلطة دموية في الوريد لعدد من 4 إلى 7 حالات من بين 1000 حالة.</p><p dir="RTL">وبالنسبة للسيدات في الخمسينات من العمر واللاتي تستخدمن العلاج بالهرمونات البديلة باستخدام هرموني الإستروجين والبروجستوجين خلال 5 سنوات، فمن المتوقع حدوث جلطة دموية لعدد من 9 إلى 12 حالة من بين 1000 حالة (أي 5 حالات زائدة).</p><p dir="RTL">أما بالنسبة للسيدات في الخمسينات من العمر واللاتي تم استئصال الرحم لديهن وتستخدمن العلاج بالهرمونات البديلة بهرمون الإستروجين فقط، خلال 5 سنوات، فمن المتوقع حدوث جلطة دموية لعدد من 5 إلى 8 حالات من بين 1000 مستخدم (أي حالة زائدة واحدة).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مرض القلب (النوبة القلبية) </strong></p><p dir="RTL">لا يوجد أي دليل على أن العلاج بالهرمونات البديلة يمنع حدوث النوبة القلبية.</p><p dir="RTL">وتعد السيدات الأكثر من 60 عاماً واللاتي تستخدمن العلاج بالهرمونات البديلة بهرموني الإستروجين والبروجستوجين أكثر عرضة بشكل بسيط لتطور مرض القلب، مقارنةً باللاتي لا تستخدمن ذلك العلاج.</p><p dir="RTL">أما بالنسبة للسيدات اللاتي تم استئصال الرحم لديهن وتستخدمن علاجاً بهرمون الإستروجين فقط، فلا توجد زيادة في مخاطر تطور مرض القلب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>السكتة الدماغية </strong></p><p dir="RTL">تعد مخاطر الإصابة بالسكتة الدماغية أعلى بمرة ونصف لدى السيدات اللاتي تستخدمن العلاج بالهرمونات البديلة مقارنةً باللاتي لا تستخدمن ذلك العلاج. وكلما تقدم العمر، يزداد عدد الحالات الزائدة العرضة للإصابة بالسكتة الدماغية الناتجة عن العلاج بالهرمونات البديلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>مقارنة </em></p><p dir="RTL">بالنسبة للسيدات في الخمسينات من العمر واللاتي لا تستخدمن العلاج بالهرمونات البديلة، فمن المتوقع، في المتوسط، حدوث سكتة دماغية لـ 8 حالات من بين 1000 حالة، خلال فترة من 5 سنوات. أما بالنسبة للسيدات في الخمسينات من العمر واللاتي تستخدمن العلاج بالهرمونات البديلة، فمن المتوقع حدوث سكتة دماغية لـ 11 حالة من بين 1000 حالة خلال 5 سنوات (أي 3 حالات زائدة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات أخرى</strong></p><p dir="RTL">لن يمنع العلاج بالهرمونات البديلة حدوث فقدان الذاكرة. ولكن توجد بعض الأدلة على أن مخاطرة الإصابة بفقدان الذاكرة تعتبر أعلى بالنسبة للسيدات اللاتي بدأن استخدام العلاج بالهرمونات البديلة بعد عمر 65 عاماً. تحدثي إلى طبيبِك في هذا الشأن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام أدوية أخرى</strong></p><p dir="RTL">الرجاء إخبار الطبيب أو الصيدلي إذا كنتِ تتناولين أو تناولتِ مؤخراً أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية. رغم ذلك، لا يُرجح أن يؤثر <strong>فاجيفم</strong><strong><sup>TM</sup></strong> على الأدوية الأخرى. ويرجع هذا إلى أن دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong> يُستخدم كعلاج موضعي في المهبل ويحتوي على جرعة ضئيلة جداً من الإيستراديول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يُستخدم دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong> للسيدات بعد سن اليأس فقط. وفي حالة حدوث حمل، بجب التوقف عن استخدام <strong>فاجيفم</strong><strong><sup>TM</sup></strong> والاتصال بالطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس له تأثير معروف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب استخدام <strong>فاجيفم</strong><strong><sup>TM</sup></strong> دوماً وفق إرشادات الطبيب. كما يجب عليك مراجعة الطبيب أو الصيدلاني إذا لم تكن واثقاً من هذا الشأن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استعمال هذا الدواء</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنكِ البدء في استعمال دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong> في أي يوم ملائم لكِ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قومي بإدخال القرص المهبلي في المهبل باستخدام الأداة المرفقة معه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشرح لكِ &quot;تعليمات المستخدم&quot; الموجودة في نهاية النشرة كيفية القيام بذلك. يرجى قراءة التعليمات بعناية قبل استخدام دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة الاستخدام</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدمي قرصاً مهبلياً واحداً كل يوم في أول أسبوعين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم استخدمي قرصاً مهبلياً واحداً مرتين في الأسبوع. اتركي 3 أو 4 أيام بين كل جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات عامة عن علاج الأعراض التي تصاحب سن اليأس</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند استخدام أدوية لعلاج أية أعراض خاصة بسن اليأس، فإنه يوصى باستخدام أقل جرعة تؤدي هذا الغرض، كما يجب استخدام الدواء لأقل فترة ممكنة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب الاستمرار في العلاج فقط إذا كانت مزايا العلاج تفوق مخاطره. تحدثي إلى طبيبِك في هذا الشأن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة أخذ جرعة زائدة من فاجيفم</strong><strong><sup>TM</sup></strong><strong>عن الجرعة الموصوفة</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا استخدمتِ كمية أكثر مما ينبغي من دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong>، فيجب التحدث إلى الطبيب أو الصيدلاني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم استخدام دواء <strong>فاجيفم</strong><strong><sup>TM</sup></strong> للعلاج الموضعي داخل المهبل. تعد جرعة الإستراديول منخفضة جداً، مما يعني أن استعمال عدد كبير من الأقراص يكافئ الجرعة المستخدمة في العلاج عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة فاجيفم</strong><strong><sup>TM</sup></strong><strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة نسيان جرعة، ينبغي استخدام الدواء في أسرع وقت بمجرد تذكره.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناولي جرعة مضاعفة لتعويض الجرعة التي فاتتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استخدام دواء فاجيفم</strong><strong><sup>TM</sup></strong></p><p dir="RTL">لا تتوقفي عن استعمال دواء ف<strong>فاجيفم</strong><strong><sup>TM</sup></strong> دون استشارة الطبيب. سوف يشرح لكِ الطبيب آثار إيقاف العلاج. كما سيناقش معكِ الاختيارات الأخرى الممكنة لعلاجِك.</p><p dir="RTL">&nbsp;</p><p>إذا كانت لديكِ أية أسئلة إضافية حول استخدامات هذا المنتج، فيمكنكِ سؤال الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، يمكن أن يسبب <strong>فاجيفم</strong><strong><sup>TM</sup></strong> آثاراً جانبية، ولكن لا يُصاب بها الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> (قد تصيب حتى شخص واحد من بين 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة أو اضطرابات أو انتفاخ البطن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف مهبلي أو إفرازات أو اضطرابات مهبلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (قد تصيب حتى شخص واحد من بين 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الأعضاء التناسلية بسبب فطريات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتوعك (غثيان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فوران حراري جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة جداً</strong> (قد تصيب حتى شخص واحد من بين 10000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الصداع النصفي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط حساسية عام (مثل التفاعلات/الصدمات التأقِيّة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تحدث الآثار الجانبية التالية مع العلاج بالإستروجين الجهازي:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض المرارة</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اضطرابات متنوعة في البشرة:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون البشرة، خاصةً في الوجه أو الرقبة والمعروف باسم &quot;بقع الحمل&quot; (الكلف)</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقيدات حمراء مؤلمة في البشرة (حمامى عقدة)</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع احمرار في شكل نقطة داخل دائرة أو قروح (حمامى عديدة الأشكال)</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال تفاقم أي من الآثار الجانبية أو إذا لاحظت ظهور آثار جانبية غير مذكورة في هذه النشرة، فيُرجى إخبار الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظه بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">ينبغي تخزين الدواء في درجة حرارة أقل من 30 درجة مئوية. لا يُخزن في الثلاجة.</p><p dir="RTL">لا يُستخدم <strong>فاجيفم</strong><strong><sup>TM</sup></strong> بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية والغلاف البلاستيكي. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">لا يجوز التخلّص من الأدوية بإلقائها في الفضلات السائلة أو المخلفات المنزلية. بل يجب استشارة الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. فهذه الإجراءات من شأنها أن تحافظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي الإيستراديول 25 ميكروجرام (في صورة نصف هيدرات الإيستراديول). يحتوي كل قرص مهبلي على 25 ميكروجرام من الإيستراديول (في صورة نصف هيدرات الإيستراديول).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي هيبروميلوس ولاكتور أحادي الهيدرات ونشا الذرة وستيارات الماغنسيوم.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي غلاف القرص على: هيبروميلوس وترياسيتين وماكروغول 6000.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يأتي كل قرص مهبلي أبيض في أداة لإدخال القرص، ويتم استخدامها لمرة واحدة فقط.</p><p dir="RTL">يظهر قرص <strong>فاجيفم</strong><strong><sup>TM</sup></strong> محفوراً عليه NOVO 278 على إحدى الجهتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات:</p><p dir="RTL">15 قرصاً مهبلياً مع أدوات الإدخال</p><p>لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p>Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vagifem®
25 micrograms
Vaginal tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vaginal tablet contains estradiol hemihydrate equivalent to estradiol 25 micrograms.

List of excipients
Tablet core: Hypromellose, lactose monohydrate, maize starch and magnesium stearate.
Film-coating: Hypromellose and macrogol 6000.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vaginal tablet.
White, film-coated, biconvex tablet, engraved with NOVO 278 on one side. Diameter 6 mm.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women (see <em>Pharmacodynamic properties</em>).</p><p>The experience of treating women older than 65 years is limited.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vagifem<sup>&reg;</sup> is administered intravaginally as a local oestrogen therapy by use of an applicator.</p><p>&nbsp;</p><p>Initial dose: One vaginal tablet daily for 2 weeks.</p><p>Maintenance dose: One vaginal tablet twice a week.</p><p>Treatment may be started on any convenient day.</p><p>&nbsp;</p><p>If a dose is forgotten, it should be taken as soon as the patient remembers. A double dose should be avoided.</p><p>&nbsp;</p><p>For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also <em>Special warnings and precautions for use</em>) should be used.</p><p>&nbsp;</p><p>Vagifem<sup>&reg;</sup> is a local vaginal therapy and in women with an intact uterus, progestagen treatment is not necessary (however see <em>Special warnings and precautions for use,</em> <em>Endometrial hyperplasia and carcinoma</em>).</p><p>&nbsp;</p><p>Vagifem<sup>&reg;</sup> may be used in women with or without an intact uterus.</p><p>&nbsp;</p><p>Vaginal infections should be treated before start of the Vagifem<sup>&reg;</sup> therapy.</p><p><strong>&nbsp;</strong></p><p><strong>Administration</strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the blister pack at the plunger end.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the applicator in the vagina until resistance is met (8-10 cm).</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Release the tablet by pressing the plunger.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the applicator and discard.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known, past or suspected breast cancer 
•	Known, past or suspected oestrogen-dependent malignant tumours (e.g. endometrial cancer)
•	Undiagnosed genital bleeding
•	Untreated endometrial hyperplasia
•	Previous or current venous thromboembolism (deep venous thrombosis, pulmonary embolism)
•	Known thrombophilic disorders (e.g. protein C, protein S or antithrombin deficiency, see Special warnings and precautions for use)
•	Active or previous arterial thromboembolic disease (e.g. angina, myocardial infarction)
•	Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal
•	Known hypersensitivity to the active substances or to any of the excipients
•	Porphyria.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the treatment of postmenopausal symptoms, HRT should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually and HRT should only be continued as long as the benefit outweighs the risk.</p><p>&nbsp;</p><p>Evidence regarding the risks associated with HRT in the treatment of premature menopause is limited. Due to the low level of absolute risk in younger women, however, the balance of benefits and risks for these women may be more favourable than in older women.</p><p>&nbsp;</p><p><em>Medical examination/follow-up</em></p><p>Before initiating or reinstituting hormone therapy, a complete personal and family medical history should be obtained. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use. During treatment, periodic check-ups are recommended of a frequency and nature adapted to the individual woman. Women should be advised what changes in their breasts should be reported to their doctor or nurse. Investigations including appropriate imaging tools, e.g. mammography, should be carried out in accordance with currently accepted screening practices, modified to the clinical needs of the individual.</p><p>&nbsp;</p><p>The pharmacokinetic profile of Vagifem<sup>&reg;</sup> shows that there is very low systemic absorption of estradiol during treatment (see <em>Pharmacokinetic properties</em>), however, being a HRT product the following need to be considered, especially for long term or repeated use of this product.</p><p>&nbsp;</p><p><em>Conditions which need supervision</em></p><p>If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be closely supervised. It should be taken into account that these conditions may recur or be aggravated during oestrogen treatment, in particular:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leiomyoma (uterine fibroids) or endometriosis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk factors for thromboembolic disorders (see below)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk factors for oestrogen-dependent tumours, e.g. 1<sup>st</sup> degree heredity for breast cancer</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver disorders (e.g. liver adenoma)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes mellitus with or without vascular involvement</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholelithiasis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine or (severe) headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic lupus erythematosus</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A history of endometrial hyperplasia (see below)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epilepsy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Otosclerosis.</p><p>&nbsp;</p><p>The pharmacokinetic profile of Vagifem<sup>&reg;</sup> shows that there is very low absorption of estradiol during treatment (see <em>Pharmacokinetic properties</em>). Due to this, the recurrence or aggravation of the above mentioned conditions is less likely than with systemic oestrogen treatment.</p><p>&nbsp;</p><p><em>Reasons for immediate withdrawal of therapy</em></p><p>Therapy should be discontinued in case a contraindication is discovered and in the following situations:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice or deterioration in liver function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significant increase in blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New onset of migraine-type headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy.</p><p>&nbsp;</p><p><em>Vagifem<sup>&reg; </sup>is a locally acting low dose estradiol preparation and therefore the occurrence of the below mentioned conditions is less likely than with systemic oestrogen treatment.</em></p><p>&nbsp;</p><p><em>Endometrial hyperplasia and carcinoma</em></p><p>Women with an intact uterus with abnormal bleeding of unknown aetiology or women with an intact uterus who have previously been treated with unopposed oestrogens, should be examined with special care in order to exclude hyperstimulation/malignancy of the endometrium before initiation of treatment with Vagifem<sup>&reg;</sup>.</p><p>&nbsp;</p><p>In women with an intact uterus, the risk of endometrial hyperplasia and carcinoma is increased when oestrogens are administered alone for prolonged periods. The reported increase in endometrial cancer risk among systemic oestrogen-only users varies from 2 to 12-fold compared with non-users, depending on both duration of treatment and on oestrogen dose. After stopping treatment, risk may remain elevated for at least 10 years.</p><p>&nbsp;</p><p>During Vagifem<sup>&reg;</sup> treatment, a minor degree of systemic absorption may occur in</p><p>some patients, especially during the first two weeks of once daily administration.</p><p>However, average plasma E2 concentrations (C<sub>ave(0-24)</sub>) at all evaluated days remained</p><p>within the normal postmenopausal range in all subjects (see <em>Pharmacokinetic properties</em>).</p><p>&nbsp;</p><p>Endometrial safety of long-term (more than one year) or repeated use of local vaginally administered oestrogen is uncertain. Therefore, if repeated, treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.</p><p>&nbsp;</p><p>As a general rule, oestrogen replacement therapy should not be prescribed for longer than one year without another physical, including gynaecological examination, being performed.</p><p>&nbsp;</p><p>If bleeding or spotting appears at any time during therapy, the reason should be investigated, which may include endometrial biopsy to exclude endometrial malignancy.</p><p>&nbsp;</p><p>The woman should be advised to contact her doctor in case bleeding or spotting occurs during treatment with Vagifem<sup>&reg;</sup>.</p><p>&nbsp;</p><p>Unopposed oestrogen stimulation may lead to premalignant or malignant transformation in the residual foci of endometriosis. Therefore caution is advised when using this product in women who have undergone hysterectomy because of endometriosis, especially if they are known to have residual endometriosis.</p><p><em>&nbsp;</em></p><p><em>Breast cancer</em></p><p>The overall evidence suggests an increased risk of breast cancer in women taking combined oestrogen-progestagen and possibly also oestrogen-only HRT, that is dependent on the duration of taking HRT.</p><p>&nbsp;</p><p>The WHI trial found no increase in risk of breast cancer in hysterectomised women using oestrogen-only HRT. Observational studies have mostly reported a small increase in risk of having breast cancer diagnosed that is substantially lower than found in users of oestrogen-progestagen combinations.</p><p>&nbsp;</p><p>The excess risk becomes apparent within a few years of use but returns to baseline within a few (at most five) years after stopping treatment.</p><p>&nbsp;</p><p>A relationship between breast cancer risk and low dose local vaginal oestrogen therapy is uncertain.</p><p>&nbsp;</p><p>HRT, especially oestrogen-progestagen combined treatment, increases the density of mammographic images which may adversely affect the radiological detection of breast cancer.</p><p>&nbsp;</p><p><em>Ovarian cancer</em></p><p>Ovarian cancer is much rarer than breast cancer.</p><p>&nbsp;</p><p>Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only <strong>systemic</strong> HRT, which becomes apparent within 5 years of use and diminishes over time after stopping.</p><p>&nbsp;</p><p>A relationship between ovarian cancer risk and low dose local vaginal oestrogen therapy is uncertain.</p><p><u>&nbsp;</u></p><p><em>Venous thromboembolism</em></p><p>HRT is associated with a 1.3 to 3-fold risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of HRT than later (see <em>Undesirable effects</em>).</p><p>&nbsp;</p><p>Patients with known thrombophilic states have an increased risk of VTE and HRT may add to this risk. HRT is therefore contraindicated in these patients (see <em>Contraindications</em>).</p><p>&nbsp;</p><p>Generally recognised risk factors for VTE include use of oestrogens, older age, major surgery, prolonged immobilisation, obesity (BMI &gt; 30 kg/m&sup2;), pregnancy/postpartum period, systemic lupus erythematosus (SLE) and cancer. There is no consensus about the possible role of varicose veins in VTE.</p><p>&nbsp;</p><p>A relationship between venous thromboembolism and low dose local vaginal oestrogen therapy is uncertain.</p><p>&nbsp;</p><p>As in all postoperative patients, prophylactic measures need to be considered to prevent VTE following surgery. If prolonged immobilisation is to follow elective surgery, temporarily stopping HRT 4 to 6 weeks earlier is recommended. Treatment should not be restarted until the woman is completely mobilised.</p><p>&nbsp;</p><p>In women with no personal history of VTE but with a first degree relative with a history of thrombosis at a young age, screening may be offered after careful counselling regarding its limitations (only a proportion of thrombophilic defects are identified by screening).</p><p>&nbsp;</p><p>If a thrombophilic defect is identified which segregates with thrombosis in family members or if the defect is &lsquo;severe&rsquo; (e.g. antithrombin, protein S or protein C deficiencies or a combination of defects) HRT is contraindicated.</p><p>&nbsp;</p><p>Women already on chronic anticoagulant treatment require careful consideration of the benefit-risk of use of HRT.</p><p>&nbsp;</p><p>If VTE develops after initiating therapy, the drug should be discontinued. Patients should be told to contact their doctors immediately when they are aware of a potential thromboembolic symptom (e.g. painful swelling of a leg, sudden pain in the chest, dyspnoea).</p><p><u>&nbsp;</u></p><p><em>Coronary artery disease (CAD)</em></p><p>There is no evidence from randomised controlled trials of protection against myocardial infarction in women with or without existing CAD who received combined oestrogen-progestagen or oestrogen-only HRT.</p><p><u>&nbsp;</u></p><p>Randomised controlled data found no increased risk of CAD in hysterectomised women using oestrogen-only therapy.</p><p><u>&nbsp;</u></p><p><em>Ischaemic stroke</em></p><p>Combined oestrogen-progestagen and oestrogen-only therapy are associated with an up to 1.5-fold increase in risk of ischaemic stroke. The relative risk does not change with age or time since menopause. However, as the baseline risk of stroke is strongly age-dependent, the overall risk of stroke in women who use HRT increases with age (see <em>Undesirable effects</em>).</p><p>&nbsp;</p><p>A relationship between ischaemic stroke and low dose local vaginal oestrogen therapy is uncertain.</p><p><u>&nbsp;</u></p><p><em>Other conditions</em></p><p>Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully observed.</p><p>&nbsp;</p><p>Women with pre-existing hypertriglyceridaemia should be followed closely during oestrogen replacement or hormone replacement therapy, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.</p><p>&nbsp;</p><p>The relationship between pre-existing hypertriglyceridaemia and low dose local vaginal oestrogen therapy is unknown.</p><p>&nbsp;</p><p>Oestrogens increase thyroid binding globulin (TBG), leading to increased circulating total thyroid hormone (as measured by protein-bound iodine (PBI)), T4 levels (by column or by radioimmunoassay) or T3 levels (by radioimmunoassay). T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Other binding proteins may be elevated in serum, i.e. corticoid binding globulin (CBG), sex-hormone-binding globulin (SHBG) leading to increased circulating corticosteroids and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).</p><p>&nbsp;</p><p>The minimal systemic absorption of estradiol with local vaginal administration (see <em>Pharmacokinetic properties</em>) is likely to result in less pronounced effects on plasma binding proteins than with systemic hormones.</p><p>&nbsp;</p><p>HRT does not improve cognitive function. There is some evidence from the WHI trial of increased risk of probable dementia in women who start using continuous combined or oestrogen-only HRT after the age of 65.</p><p>&nbsp;</p><p>Intravaginal applicators may cause minor local trauma, especially in women with serious vaginal atrophy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As the oestrogen in Vagifem<sup>&reg;</sup> is administered within the vagina and due to the low levels of estradiol released, it is unlikely that any clinically relevant drug interactions will occur with Vagifem<sup>&reg;</sup>.</p><p>However, the metabolism of oestrogens may be increased by concomitant use of substances known to induce drug-metabolising enzymes, specifically cytochrome P450 enzymes, such as anticonvulsants (e.g. phenobarbital, phenytoin, carbamazepine) and anti-infectives (e.g. rifampicin, rifabutin, nevirapine, efavirenz).</p><p>Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones. Herbal preparations containing St John&rsquo;s Wort (<em>Hypericum perforatum</em>) may induce the metabolism of oestrogens.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>Vagifem<sup>&reg;</sup> is not indicated during pregnancy. If pregnancy occurs during medication with Vagifem<sup>&reg;</sup>, treatment should be withdrawn immediately. The results of most epidemiological studies to date relevant to inadvertent foetal exposure to oestrogens indicate no teratogenic or foetotoxic effects.</p><p><u>&nbsp;</u></p><p><em>Lactation</em></p><p>Vagifem<sup>&reg;</sup> is not indicated during lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effects known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Adverse events from clinical trials</em></p><p>More than 673 patients have been treated with Vagifem<sup>&reg;</sup> 10 micrograms in clinical trials, including over 497 patients treated up to 52 weeks.</p><p>Oestrogen-related adverse events such as breast pain, peripheral oedema and postmenopausal bleedings have been reported at very low rates, similar to placebo, with Vagifem<sup>&reg;</sup> 10 micrograms, but if they occur, they are most likely present only at the beginning of the treatment. The adverse events observed with a higher frequency in patients treated with Vagifem<sup>&reg;</sup> 10 micrograms as compared to placebo and which are possibly related to treatment are presented below.</p><p>&nbsp;</p><p><strong>Common (&ge; 1/100; &lt; 1/10)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervous system disorders: headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal disorders: abdominal pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reproductive system and breast disorders: vaginal haemorrhage, vaginal discharge or vaginal discomfort.</p><p>&nbsp;</p><p><strong>Uncommon (&ge; 1/1,000; &lt; 1/100)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections and infestations: vulvovaginal mycotic infection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal disorders: nausea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and subcutaneous tissue disorders: rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investigations: weight increased</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vascular disorders: hot flush, hypertension.</p><p>&nbsp;</p><p><em>Post-marketing experience</em></p><p>In addition to the above mentioned adverse drug reactions, those presented below have been spontaneously reported for patients being treated with Vagifem<sup>&reg;</sup> 25 micrograms, and are considered possibly related to treatment. The reporting rate of these spontaneous adverse reactions is very rare (&lt; 1/10,000 patient years).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neoplasms benign and malignant (including cysts and polyps): breast cancer, endometrial cancer</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune system disorders: generalised hypersensitivity reactions (e.g. anaphylactic reaction/shock)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolism and nutrition disorders: fluid retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psychiatric disorders: insomnia, depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervous system disorders: migraine aggravated</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vascular disorders: deep venous thrombosis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal disorders: diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and subcutaneous tissue disorders: urticaria, rash erythematous, rash pruritic, genital pruritus</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reproductive system and breast disorders: endometrial hyperplasia, vaginal irritation, vaginal pain, vaginismus, vaginal ulceration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General disorders and administration site conditions: drug ineffective</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investigations: weight increased, blood oestrogen increased.</p><p>&nbsp;</p><p>Other adverse reactions have been reported in association with oestrogen treatment.</p><p>Risk estimates have been drawn from systemic exposure and it is not known how these apply to local treatments:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myocardial infarction, congestive heart disease</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gall bladder disease</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and subcutaneous disorders: chloasma, erythema multiforme, erythema nodosum, vascular purpura</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in size of fibroids</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epilepsy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Libido disorder</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deterioration of asthma</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probable dementia over the age of 65 (see <em>Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p><strong>Breast cancer risk</strong></p><p>Risk estimates have been drawn from systemic exposure and it is not known how these apply to local treatments.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An up to 2-fold increased risk of having breast cancer diagnosed is reported in women taking combined oestrogen-progestagen therapy for more than 5 years.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any increased risk in users of oestrogen-only therapy is substantially lower than that seen in users of oestrogen-progestagen combinations.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The level of risk is dependent on the duration of use (see <em>Special warnings and precautions for use</em>).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results of the largest randomised placebo-controlled trial (WHI-study) and largest epidemiological study (MWS) are presented.</p><p><u>&nbsp;</u></p><p><strong>Million Women Study &ndash; Estimated additional risk of breast cancer after 5 years&rsquo; use</strong></p><p>&nbsp;</p><p><strong>Oestrogen-only HRT</strong></p><p>Age range (years): 50-65</p><p>Incidence per 1,000 never-users of HRT over a 5-year period*: 9-12</p><p>Risk ratio and 95%CI **: 1.2</p><p>Additional cases per 1,000 HRT users over 5 years (95%CI): 1-2 (0-3)</p><p>&nbsp;</p><p><strong>Combined oestrogen-progestagen</strong></p><p>Age range (years): 50-65</p><p>Incidence per 1,000 never-users of HRT over a 5-year period*: 9-12</p><p>Risk ratio and 95%CI **: 1.7</p><p>Additional cases per 1,000 HRT users over 5 years (95%CI): 6 (5-7)</p><p>&nbsp;</p><p>* Taken from baseline incidence rates in developed countries.</p><p>** Overall risk ratio. The risk ratio is not constant but will increase with increasing duration on use.</p><p>Note: Since the background incidence of breast cancer differs by EU country, the number of additional cases of breast cancer will also change proportionately.</p><p>&nbsp;</p><p><strong>US WHI Studies &ndash; Additional risk of breast cancer after 5 years&rsquo; use</strong></p><p>&nbsp;</p><p><strong>CEE oestrogen-only</strong></p><p>Age range (years): 50-79</p><p>Incidence per 1,000 women in placebo arm over 5 years: 21</p><p>Risk ratio and 95%CI: 0.8 (0.7-1.0)</p><p>Additional cases per 1,000 HRT users over 5 years (95%CI): -4 (-6-0)*</p><p>&nbsp;</p><p><strong>CEE+MPA oestrogen-progestagen**</strong></p><p>Age range (years): 50-79</p><p>Incidence per 1,000 women in placebo arm over 5 years: 17</p><p>Risk ratio and 95%CI: 1.2 (1.0-1.5)</p><p>Additional cases per 1,000 HRT users over 5 years (95%CI): 4 (0-9)</p><p>&nbsp;</p><p>* WHI study in women with no uterus, which did not show an increase in risk of breast cancer.</p><p>** When the analysis was restricted to women who had not used HRT prior to the study there was no increased risk apparent during the first 5 years of treatment: after 5 years the risk was higher than in non-users.</p><p>&nbsp;</p><p><em>Endometrial cancer risk</em></p><p><u>Postmenopausal women with a uterus</u></p><p>The endometrial cancer risk is about 5 in every 1,000 women with a uterus not using HRT.</p><p>In women with a uterus, use of systemic oestrogen-only HRT is not recommended because it increases the risk of endometrial cancer (see <em>Special warnings and precautions for use</em>).</p><p>Depending on the duration of systemic oestrogen-only use and oestrogen dose, the increase in risk of endometrial cancer in epidemiology studies varied from between 5 and 55 extra cases diagnosed in every 1,000 women between the ages of 50 and 65.</p><p>Adding a progestagen to systemic oestrogen-only therapy for at least 12 days per cycle can prevent this increased risk. In the Million Women Study the use of five years of combined (sequential or continuous) HRT did not increase risk of endometrial cancer (RR of 1.0 (0.8-1.2)).</p><p>Please also see <em>Special warnings and precautions for use.</em></p><p>&nbsp;</p><p><em>Ovarian cancer</em></p><p>Risk estimates have been drawn from systemic exposure and it is not known how these apply to local treatments.</p><p>Use of <strong>systemic</strong> HRT has been associated with a slightly increased risk of having ovarian cancer diagnosed (see <em>Special warnings and precautions for use</em>).</p><p>A meta-analysis from 52 epidemiological studies reported an increased risk of ovarian cancer in women currently using systemic HRT compared to women who have never used HRT (RR 1.43, 95% CI 1.31&ndash;1.56). For women aged 50 to 54 years taking 5 years of HRT, this results in about 1 extra case per 2,000 users. In women aged 50 to 54 who are not taking HRT, about 2 women in 2,000 will be diagnosed with ovarian cancer over a 5-year period.</p><p>&nbsp;</p><p><em>Risk of venous thromboembolism</em></p><p>Risk estimates have been drawn from systemic exposure and it is not known how these apply to local treatments.</p><p>HRT is associated with a 1.3 to 3-fold increased relative risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of using HRT (see <em>Special warnings and precautions for use</em>). Results of the WHI studies are presented:</p><p>&nbsp;</p><p><strong>WHI Studies &ndash; Additional risk of VTE over 5 years&rsquo; use</strong></p><p><strong>&nbsp;</strong></p><p><strong>Oral oestrogen-only*</strong></p><p>Age range (years): 50-59</p><p>Incidence per 1,000 women in placebo arm over 5 years: 7</p><p>Risk ratio and 95%CI: 1.2 (0.6-2.4)</p><p>Additional cases per 1,000 HRT users: 1 (-3-10)</p><p>&nbsp;</p><p><strong>Oral combined oestrogen-progestagen</strong></p><p>Age range (years): 50-59</p><p>Incidence per 1,000 women in placebo arm over 5 years: 4</p><p>Risk ratio and 95%CI: 2.3 (1.2-4.3)</p><p>Additional cases per 1,000 HRT users: 5 (1-13)</p><p>&nbsp;</p><p>* Study in women with no uterus.</p><p>&nbsp;</p><p><em>Risk of coronary artery disease</em></p><p>Risk estimates have been drawn from systemic exposure and it is not known how these apply to local treatments.</p><p>&nbsp;</p><p>The risk of coronary artery disease is slightly increased in users of combined oestrogen-progestagen HRT over the age of 60 (see <em>Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p><em>Risk of ischaemic stroke</em></p><p>Risk estimates have been drawn from systemic exposure and it is not known how these apply to local treatments.</p><p>&nbsp;</p><p>The use of oestrogen-only and oestrogen-progestagen therapy is associated with an up to 1.5-fold increased relative risk of ischaemic stroke. The risk of haemorrhagic stroke is not increased during use of HRT.</p><p>&nbsp;</p><p>This relative risk is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of stroke in women who use HRT will increase with age, see <em>Special warnings and precautions for use.</em></p><p>&nbsp;</p><p><strong>WHI Studies combined &ndash; Additional risk of ischaemic stroke* over 5 years&rsquo; use</strong></p><p>&nbsp;</p><p>Age range (years): 50-59</p><p>Incidence per 1,000 women in placebo arm over 5 years: 8</p><p>Risk ratio and 95%CI: 1.3 (1.1-1.6)</p><p>Additional cases per 1,000 HRT users over 5 years: 3 (1-5)</p><p>&nbsp;</p><p>* No differentiation was made between ischaemic and haemorrhagic stroke.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vagifem<sup>&reg;</sup> is intended for intravaginal use and the dose of estradiol is very low. Overdose is therefore unlikely, but if it occurs, treatment is symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Natural and semisynthetic oestrogens, plain. ATC code: G03CA03.</p><p>&nbsp;</p><p>The active ingredient, synthetic 17&beta;-estradiol, is chemically and biologically identical to endogenous human estradiol.</p><p>Endogenous 17&beta;-estradiol induces and maintains the primary and secondary female sexual characteristics. The biological effect of 17&beta;-estradiol is carried out through a number of specific oestrogen receptors. The steroid receptor complex is bound to the cells DNA and induces synthesis of specific proteins.</p><p>Maturation of the vaginal epithelium is dependent upon oestrogens. Oestrogens increase the number of superficial and intermediate cells and decrease the number of basal cells in vaginal smear.</p><p>Oestrogens maintain vaginal pH around normal range (4.5) which enhances normal bacterial flora.</p><p>A 12-months, double-blind, randomised, parallel group, placebo-controlled, multicentre study was conducted to evaluate the efficacy and safety of Vagifem<sup>&reg;</sup> 10 micrograms in the treatment of postmenopausal vaginal atrophy symptoms.</p><p>After 12 weeks of treatment with Vagifem<sup>&reg;</sup> 10 micrograms the change from baseline, in comparison with placebo treatment, demonstrated significant improvements in the 3 primary endpoints: Vaginal Maturation Index and Value, normalisation of vaginal pH and relief of the moderate/severe urogenital symptoms considered most bothersome by the subjects.</p><p>Endometrial safety of Vagifem<sup>&reg;</sup> 10 micrograms was evaluated in the above mentioned trial and a second, open-label, multicentre trial. In total, 386 women underwent endometrial biopsy at the beginning and at the end of 52 weeks treatment. Incidence rate of hyperplasia and/or carcinoma was 0.52% (95% CI 0.06%, 1.86%), indicating no increased risk.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>Oestrogens are well absorbed through the skin, mucous membranes and the gastrointestinal tract. After vaginal administration, estradiol is absorbed circumventing first-pass metabolism.</p><p>A 12-weeks, single-centre, randomised, open label, multiple dose, parallel-group trial was conducted to evaluate the extent of systemic absorption of estradiol from the Vagifem<sup>&reg;</sup> 10 micrograms tablet. Subjects were randomised 1:1 to receive either 10 micrograms or 25 micrograms Vagifem<sup>&reg;</sup>. Plasma levels of estradiol (E2), oestrone (E1) and oestrone sulfate (E1S) were determined. The AUC<sub>(0-24)</sub> for plasma E2 levels increased almost proportionally after the administration of 10 micrograms and 25 micrograms Vagifem<sup>&reg;</sup>. The AUC<sub>(0-24)</sub> indicated higher systemic estradiol levels for the 10 micrograms E2 tablet as compared to baseline on treatment days 1, 14 and 83, being statistically significant at days 1 and 14 (Table 1). However, average plasma E2 concentrations (C<sub>ave (0-24)</sub>) at all evaluated days remained within the normal postmenopausal range in all subjects. The data from days 82 and 83 as compared to baseline indicate that there is no cumulative effect during twice weekly maintenance therapy.</p><p>&nbsp;</p><p><strong>Table 1 Values of PK parameters from plasma Estradiol (E2) concentrations: Study VAG-1850</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:503px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Vagifem<sup>&reg;</sup> 10</strong> <strong>micrograms </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AUC<sub>(0-24)</sub></p><p>pg.h/ml</p><p>(geom. mean)</p></td><td style="vertical-align:top"><p>C<sub>ave(0-24)</sub></p><p>pg/ml</p><p>(geom. mean)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Day -1</p></td><td style="vertical-align:top"><p>75.65</p></td><td style="vertical-align:top"><p>3.15</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>225.35</p></td><td style="vertical-align:top"><p>9.39</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Day 14</p></td><td style="vertical-align:top"><p>157.47</p></td><td style="vertical-align:top"><p>6.56</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Day 82</p></td><td style="vertical-align:top"><p>44.95</p></td><td style="vertical-align:top"><p>1.87</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Day 83</p></td><td style="vertical-align:top"><p>111.41</p></td><td style="vertical-align:top"><p>4.64</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The levels of oestrone and oestrone sulfate seen after 12 weeks of Vagifem<sup>&reg;</sup> 10 micrograms administration did not exceed baseline levels, i.e. no accumulation of oestrone or oestrone sulfate was observed.</p><p><em>&nbsp;</em></p><p><em>Distribution</em></p><p>The distribution of exogenous oestrogens is similar to that of endogenous oestrogens. Oestrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Oestrogens circulate in the blood largely bound to sex hormone binding globulin (SHBG) and albumin.</p><p><em>&nbsp;</em></p><p><em>Biotransformation</em></p><p>Exogenous oestrogens are metabolised in the same manner as endogenous oestrogens. The metabolic transformations take place mainly in the liver. Estradiol is converted reversibly to oestrone, and both can be converted to estriol, which is the major urinary metabolite. In postmenopausal women, a significant portion of the circulating oestrogens exist as sulfate conjugates, especially oestrone sulfate, which serves as a circulating reservoir for the formation of more active oestrogens.</p><p>&nbsp;</p><p><em>Elimination</em></p><p>Estradiol, oestrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates.</p><p>&nbsp;</p><p><em>Special patient groups</em></p><p>The extent of systemic absorption of estradiol during treatment with Vagifem<sup>&reg;</sup> 10 micrograms has been evaluated in postmenopausal women aged 60-70 (mean age 65.4) only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>17&beta;-Estradiol is a well-known substance. Nonclinical studies provided no additional data of relevance to clinical safety beyond those already included in other sections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core: Hypromellose, lactose monohydrate, maize starch and magnesium stearate.</p><p>Film-coating: Hypromellose and macrogol 6000.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C. Do not refrigerate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each tablet is contained in a disposable, single-use, polyethylene/polypropylene applicator. The applicators are packed separately in PVC/aluminium foil blisters.</p><p>15-packs applicators with inset tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>